摘要Metabolic dysfunction-associated steatotic liver disease(MASLD)has emerged as the most prevalent chronic liver disorder worldwide,characterized by complex molecular regulatory networks driving its pathogenesis.Non-coding RNAs(ncRNAs),including microRNAs(miRNAs),long non-coding RNAs(lncRNAs),and circular RNAs(circRNAs),serve as critical regulators of gene expression and have been increasingly recognized for their pivotal roles in MASLD development.Rather than functioning in isolation,these ncRNAs form intricate regulatory networks that integrate and amplify disease signals across multiple cellular compartments and pathological stages.This review provides a comprehensive overview of how these ncRNA networks orchestrate MASLD progression,focusing on their roles in metabolic dysregulation,inflammation,and fibrosis.We further evaluate the diagnostic potential of circulating ncRNAs as stable,non-invasive biomarkers for disease stratification and monitoring,and discuss emerging therapeutic strategies targeting ncRNAs,including antisense oligonucleotides,syn-thetic mimics,and advanced delivery platforms such as lipid nanoparticles and engineered exosomes.Despite significant progress,challenges related to delivery efficiency,tissue specificity,and safety remain barriers to clinical translation.By synthesizing current knowledge of ncRNA networks in MASLD and highlighting opportunities for therapeutic intervention,this review provides a roadmap for translating ncRNAs into clinical applications for this increasingly prevalent metabolic liver disease.